OnCo

Ewing sarcoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Advanced, first line2
Second line1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersLocalisedInterval-compressed VDC/IE ×14 cycles (AEWS0031 / Euro Ewing 2012) with surgery ± radiotherapy (or definitive RT 55.8 Gy) after 6 induction cycles.91

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic (lung only)Same chemotherapy plus whole-lung irradiation; busulfan-melphalan high-dose therapy in selected patients (Euro-EWING 99 R2pulm equivocal).79
All comersMetastatic (bone/marrow)Chemotherapy with palliative-intent local therapy; survival <20%; trials strongly preferred.79

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRelapsedHigh-dose ifosfamide (rEECur), irinotecan-temozolomide, topotecan-cyclophosphamide, gemcitabine-docetaxel; local therapy; trials.85

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.